Drug Profile
Lamivudine/maraviroc/zidovudine
Alternative Names: GSK 2838510; Lamivudine/zidovudine/maraviroc; Maraviroc/lamivudine/zidovudine; Maraviroc/zidovudine/lamivudine; Zidovudine/lamivudine/maraviroc; Zidovudine/maraviroc/lamivudineLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiretrovirals; Azides; Cyclohexanes; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules; Triazoles
- Mechanism of Action CCR5 receptor antagonists; Nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in USA (PO, Tablet)
- 31 Jan 2012 GlaxoSmithKline completes a Phase-I bioequivalence trial in HIV-1 infections (in volunteers) in USA (NCT01597648)
- 01 Nov 2011 Phase-I clinical trials in HIV-1 infections (in volunteers) in USA (PO)